Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05445778 · ClinicalTrials.gov registry record · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
A Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT05445778 is a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 520 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05445778, a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Mirvetuximab soravtansine plus Bevacizumab
Study Locations (20)
California
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 269573 - Irvine
- Moores Cancer Center at UC San Diego /ID# 269564 - La Jolla
- Kaiser Permanente - Los Angeles Medical Center /ID# 269541 - Los Angeles
- University Of California Irvine Medical Center /ID# 269572 - Orange
- Stanford Women'S Cancer Center /ID# 269552 - Palo Alto
- Kaiser Permanente - Riverside Medical Center /ID# 269539 - Riverside
- Kaiser Permanente Zion Medical Center /ID# 269537 - San Diego
- Kaiser Permanente - San Diego Medical Center /ID# 269540 - San Diego
- Kaiser Permanente - San Marcos Medical Offices /ID# 269542 - San Marcos
- Olive View-Ucla Medical Center /ID# 269584 - Sylmar
- John Muir Health - Walnut Creek Medical Center /ID# 269575 - Walnut Creek
Florida
- Broward General Medical Center /ID# 269577 - Fort Lauderdale
- Regional Cancer Center /ID# 269558 - Fort Myers
- Baptist Md Anderson Cancer Center - Jacksonville - Palm Avenue /ID# 269560 - Jacksonville
- Mount Sinai Medical Center /ID# 269582 - Miami
- Sarasota Memorial Hospital /ID# 269526 - Sarasota
Alabama
- Usa Mitchell Cancer Institute /ID# 269661 - Mobile
Arizona
- Honorhealth Virginia G. Piper Cancer Care Network - Biltmore /ID# 269987 - Phoenix
Georgia
- Northside Hospital /ID# 269660 - Atlanta
Illinois
- Rush University Medical Center /ID# 269583 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2032-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05445778
The ClinicalTrials.gov registry entry for NCT05445778 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (28% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT05445778 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05445778 about?
NCT05445778 is a clinical study titled "Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer". GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expre...
What is the current status of trial NCT05445778?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 520 participants. The study started on 2023-03-15. Estimated completion is 2032-05.
What conditions does trial NCT05445778 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT05445778?
The interventions under investigation include: Bevacizumab (DRUG), Mirvetuximab soravtansine plus Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT05445778?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05445778 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.